French pharmaceutical company Ipsen has collaborated with Dassault Systèmes to develop new and effective programmes to support its drug discovery.

Under the terms, Ipsen will deploy Dassault’s 3DEXPERIENCE platform to accelerate its research and development (R&D), transformation and discovery of new therapeutic solutions.

The 3DEXPERIENCE platform is a business experience platform that is available on premises and in public or private cloud, Dassault said.

It offers data integration, modelling and simulation capabilities to better understand dysregulations linked to diseases.

The 3DEXPERIENCE platform also improves and shortens the identification of quality drug candidates.

Dassault Systèmes life sciences industry vice-president Jean Colombel said: "The virtual world offers the pharmaceutical industry opportunities to reinvent collaboration, connect unrelated disciplines and simulate human biological complex phenomena like never before.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The 3DEXPERIENCE platform also improves and shortens the identification of quality drug candidates."

"Our partnership with Ipsen on the adoption of the 3DEXPERIENCE platform furthers the promise of the 3D experience approach by bridging life sciences disciplines and delivering innovative patient experiences."

The project also aims to optimise the R&D processes of Ipsen’s multi-disciplinary teams in the biotechnological and life sciences hubs in France, the UK and the US.

Ipsen R&D executive vice-president Claude Bertrand said: "After more than five years of partnering with Dassault Systèmes on the BioIntelligence, we are pleased to achieve a key step in our collaboration with the deployment of this set of cutting edge innovative tools.

"Ipsen as a key scientific partner has open innovation in its DNA and this new collaborative and innovative digital platform will support Ipsen’s commitment to achieve therapeutic breakthroughs in patient care."

Ipsen primarily develops and markets medications used in oncology, endocrinology and the treatment of neuromuscular disorders.

Image: 3DEXPERIENCE platform improves and shortens the identification of quality drug candidates. Photo: courtesy of Dassault Systèmes.